Table 2.

Association between serum selenium status and prostate cancer risk in the EPIC-Heidelberg nested case-control study (n = 740)

Quartiles of serum selenium concentration (μg/L)Continuous (per 10 μg/L)
<78.978.9-87.087.0-95.0≥95.0
Cases/controls (n)69/11666/12543/12266/127
Crude OR* (95% CI)1.000.90 (0.58, 1.40)0.60 (0.38, 0.95)0.89 (0.58, 1.37)0.92 (0.82, 1.04)
Adjusted OR (95% CI)1.000.92 (0.59, 1.43)0.61 (0.38, 0.98)0.78 (0.49, 1.22)0.89 (0.79, 1.01)
Excluding cases diagnosed during 1st year of follow-up (and matched controls)
Cases/controls (n)68/11259/11640/11764/119
Adjusted OR (95% CI)1.000.87 (0.55, 1.37)0.57 (0.35, 0.92)0.79 (0.50, 1.25)0.89 (0.78, 1.01)
High-grade prostate cancer
Cases/controls (n)31/3721/4612/4126/56
Adjusted OR (95% CI)1.000.53 (0.25, 1.12)0.34 (0.15, 0.79)0.50 (0.24, 1.03)0.84 (0.69, 1.02)
Low-grade prostate cancer
Cases/controls (n)35/6831/6726/6736/56
Adjusted OR (95% CI)1.000.91 (0.48, 1.71)0.75 (0.40, 1.41)1.10 (0.58, 2.09)0.96 (0.81, 1.15)
  • *Crude OR from conditional logistic regression stratified by matching factors (age group and time of recruitment).

  • Adjusted OR additionally adjusted for family history of prostate cancer, participation in PSA testing, smoking status, and vigorous physical activity.